Multiple Myeloma

FDA Approves Belantamab Mafodotin-blmf to Treat Relapsed/Refractory Multiple Myeloma
August 06, 2020

The FDA approved the first anti-BCMA therapy, belantamab mafodotin-blmf, to treat patients with relapsed/refractory multiple myeloma who have received 4 prior therapies.

Daratumumab Combo Meets Primary End Point in Relapsed/Refractory Multiple Myeloma
August 03, 2020

The study is evaluating the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone as treatment for patients with relapsed or refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, Discusses Second Malignancies and Second Transplants in Multiple Myeloma Treatment
July 18, 2020

Parameswaran Hari, MD, MRCP, discussed second malignancies and second transplants for patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.